Free Trial
NASDAQ:CLDX

Celldex Therapeutics Q1 2024 Earnings Report

Celldex Therapeutics logo
$19.26 +0.60 (+3.22%)
As of 09:51 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Celldex Therapeutics EPS Results

Actual EPS
-$0.56
Consensus EPS
-$0.67
Beat/Miss
Beat by +$0.11
One Year Ago EPS
N/A

Celldex Therapeutics Revenue Results

Actual Revenue
$0.16 million
Expected Revenue
$1.30 million
Beat/Miss
Missed by -$1.14 million
YoY Revenue Growth
N/A

Celldex Therapeutics Announcement Details

Quarter
Q1 2024
Time
N/A
Conference Call Date
Monday, May 6, 2024
Conference Call Time
7:00AM ET

Upcoming Earnings

Celldex Therapeutics' Q2 2025 earnings is scheduled for Thursday, August 14, 2025, with a conference call scheduled on Thursday, August 7, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Celldex Therapeutics Earnings Headlines

Trump wipes out trillions overnight…
Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out nearly $5 trillion in wealth from the S&P 500 and $6.4 trillion from the Dow Jones… Not to mention the countless trillions of dollars lost in every market around the world… leaving the major political powers scrambling in fear of Trump’s next move.
See More Celldex Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Celldex Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Celldex Therapeutics and other key companies, straight to your email.

About Celldex Therapeutics

Celldex Therapeutics (NASDAQ:CLDX), a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.

View Celldex Therapeutics Profile

More Earnings Resources from MarketBeat